|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Gilead Sciences Inc.: PharmaVitae Model
|
Jan 2009 |
£3,605 |
100% |
|
Gilead Sciences: Corporate Analysis
|
May 2008 |
£255 |
99% |
Gilead Sciences
PharmaVitae Profile
|
Oct 2010 |
£3,605 |
99% |
|
Gilead Sciences Inc-Therapeutic Competitors
|
Mar 2011 |
£220 |
99% |
|
Gilead Sciences Inc-Detailed Product Pipeline
|
Mar 2011 |
£475 |
99% |
|
Gilead Sciences: Pipeline, Products, Performance, Potential
|
Feb 2010 |
£595 |
99% |
Gilead Sciences, Inc. - Pharmaceuticals & Healthcare
Deals and Alliances Profile
|
Jul 2009 |
£160 |
98% |
|
Gilead Sciences Inc-Deals & Alliances Report
|
Mar 2011 |
£380 |
98% |
Gilead Sciences, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
97% |
Top 10 Biotech Companies
Market Outlook, 2008-2023
|
Jan 2009 |
£1,499 |
90% |
Key Companies: HIV
Companies co-operate and co-formulate to stay competitive in a tight HIV market
|
Jun 2011 |
£2,405 |
90% |
|
HIV Drugs
|
Apr 2010 |
£2,815 |
89% |
|
Cystic Fibrosis
|
Jun 2010 |
£2,500 |
86% |
Gilead to Acquire Pharmasset for $11 Billion
Deal Analysis from GlobalData
|
Nov 2011 |
£315 |
86% |
Global Antivirals Market
2010-2025
|
Feb 2010 |
£1,499 |
79% |
Idiopathic Pulmonary Fibrosis
Pipeline Assessment and Market Forecasts to 2017
|
Jul 2010 |
£1,265 |
78% |
Hepatitis B
Drug Pipeline Analysis and Market Forecasts to 2016
|
May 2010 |
£1,265 |
77% |
Diastolic Heart Failure Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
76% |
Bristol-Myers Squibb Company - Pharmaceuticals & Healthcare
Deals and Alliances Profile
|
Jul 2009 |
£160 |
76% |
Congenital Lung Disease Global Clinical Trials Review
Q1, 2011
|
Jan 2011 |
£630 |
76% |
Non-Alcoholic Steatohepatitis Global Clinical Trials Review
Q1, 2011
|
Apr 2011 |
£630 |
76% |
Chronic Stable Angina Global Clinical Trials Review
Q2, 2011
|
May 2011 |
£630 |
75% |
Herpes Simplex Global Clinical Trials Review
Q1, 2011
|
Apr 2011 |
£630 |
75% |
Angina Global Clinical Trials Review
Q4, 2010
|
Dec 2010 |
£630 |
75% |
Partnering and M&A Yearbook
2012
|
Jan 2012 |
£2,210 |
74% |
Partnering Yearbook
2012
|
Jan 2012 |
£1,895 |
74% |
Nonalcoholic Steatohepatitis Therapeutics
Pipeline Assessment and Market Forecasts to 2017
|
Dec 2010 |
£1,265 |
74% |
|
Global Biotechnology Industry 2006
|
Jun 2006 |
£550 |
74% |
Top 10 Biotechnology Companies
SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline
|
Feb 2010 |
£2,215 |
74% |
|
Hepatitis B - Pipeline Assessment and Market Forecasts to 2017
|
Sep 2010 |
£1,265 |
74% |
